Fludarabine in the treatment of chronic lymphocytic leukemia: a review

References

• CLL Trialists’ Collaborative GroupChemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trialsJ Natl Cancer Inst19999186186810340906
   PubMed Web of Science ®Google Scholar
• BarruecoJRJacobsenDMChangC-HProposed mechanism of therapeutic selectivity of 9-β-D-arabinofuranosyl-2-fluoroadenine against murine leukemia based upon lower capacities for transport and phosphorylation in proliferative intestinal epithelium compared to tumor cellsCancer Res1987477007063802076
   PubMed Web of Science ®Google Scholar
• RossSRMcTavishDFauldsDFludarabine: a review of its pharmacological properties and therapeutic potential in malignancyDrugs1993457377597686467
   PubMed Web of Science ®Google Scholar
• PlunkettWGandhiVCellular metabolism of nucleoside analogs in CLL: implications for drug developmentChesonBChronic lymphocytic leukemia – scientific advances and clinical developments.New YorkMarcel Dekker1992197219
   Google Scholar
• PlunkettWGandhiVHuangPFludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapySemin Oncol1993202128235690
   PubMed Web of Science ®Google Scholar
• AvramisVIPlunkettWMetabolism and therapeutic efficacy of 9-β-D-arabinofuranosyl-2-fluoroadenine against murine leukemia P388Cancer Res198242258725917083151
   PubMed Web of Science ®Google Scholar
• DanhauserLPlunkettWKeatingM9-β-D-Arabinofuranosyl-2-fluoroadenine 5’-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukaemia and lymphomaCancer Chemother Pharmacol1996181451522431803
   PubMed Web of Science ®Google Scholar
• KemenaAKeatingMJPlunkettWPlasma and cellular bioavailability of oral fludarabineBlood19917852a
   Google Scholar
• DanhauserLPlunkettWLiliemarkJComparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5’-monophosphate in patient with relapsed leukemiaLeukemia198716386433478543
   PubMed Web of Science ®Google Scholar
• KemenaAGandhiVShewachDSInhibition of fludarabine metabolism by arabinosylcytosine during therapyCancer Chemother Pharmacol1992311931991464155
   PubMed Web of Science ®Google Scholar
• GandhiVKemenaAKeatingMJCellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukaemia cells during fludarabine therapyLeuk Lymphoma19931049568374523
   PubMed Web of Science ®Google Scholar
• KeatingMJO’BrienSKantarjianHLong-term follow-up of patients with chronic lymphocytic leukaemia treated with fludarabine as a single agentBlood199381287828848499626
   PubMed Web of Science ®Google Scholar
• KeatingMJO’BrienSLernerSLong-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapyBlood199892116511719694704
   PubMed Web of Science ®Google Scholar
• ForanJMOscierDOrchardJPharmacokinetic study of single doses of oral fludarabine phosphate in patients with ‘low-grade’ non-Hodgkin’s lymphoma and B-cell chronic lymphocytic leukemiaJ Clin Oncol1999171574157910334546
   PubMed Web of Science ®Google Scholar
• OscierDOrchardJACulliganDThe bioavailability of oral fludarabine phosphate is unaffected by foodThe Hematol J20012316321
   PubMedGoogle Scholar
• O’RourkeTJBurrisHARodriguezGIPhase I pharmacokinetic and bioavailability study of five daily intravenous and oral doses of fludarabine phosphate in patients with advanced cancerProc Am Soc Clin Oncol199716210
   Web of Science ®Google Scholar
• OgawaYHottaTTobinaiKPhase I and pharmacokinetic study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin’s lymphomaAnn Oncol20061733033316275653
   PubMed Web of Science ®Google Scholar
• BrockmanRWSchabelFMJrMontgomeryJABiological activity of 9-β-D-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-β-D-arabinofuranosyladenineBiochem Pharmacol19972621932196563233
   PubMed Web of Science ®Google Scholar
• PlunkettWAlexanderLChubbSComparison of the toxicity and metabolism of 9-β-D-arabinofuranosyl-2-fluoroadenine and 9–β-D-arabinofuranosyladenine in human lymphoblastoid cellsCancer Res198040234923456966966
   PubMed Web of Science ®Google Scholar
• PlunkettWSaundersPPMetabolism and action of purine nucleoside analogsPharmacol Ther19914923392368
   Web of Science ®Google Scholar
• CatapanoCVPerrinoFWFernandesDJPrimer RNA chain termination induced by 9-beta-D-arabinofuranosyl-2-fluoroadenine 5’-triphosphate: a mechanism for DNA synthesis inhibitionJ Biol Chem1993268717971857681821
   PubMed Web of Science ®Google Scholar
• ParkerWChengYCInhibition of DNA primase by nucleoside triphosphates and their arabinofuranosyl analogsMol Pharmacol1987311461513807892
   PubMed Web of Science ®Google Scholar
• ParkerWBBapatARShenJ-XInteraction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymer-ases, DNA primase and ribonucleotide reductaseMol Pharmacol1988344854913050447
   PubMed Web of Science ®Google Scholar
• TsengWCDerseDChengY-CIn vitro activity of 9-β-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cellsMol Pharmacol1982214744777048062
   PubMed Web of Science ®Google Scholar
• WhiteLShaddixSCBrockmanRWComparison of the actions of 9-β-D-arabinofuranosyl-2-fluoroadenine and 9-β-D-arabinofuranosyladenine on target enzymes from mouse tumor cellsCancer Res198242226022647042080
   PubMed Web of Science ®Google Scholar
• SpriggsDRobbinsGMitchellTIncorporation of 9-β-D-arabinofuranosyl–2-fluoroadenine into HL-60 cellular RNA and DNABiochem Pharmacol1986352472523942598
   PubMed Web of Science ®Google Scholar
• HuangPChubbSPlunkettWTermination of DNA synthesis by 9-β-D-arabinofuranosyl–2-fluoroadenine: a mechanism for cytotoxicityJ Biol Chem199026516617166251697861
   PubMed Web of Science ®Google Scholar
• HuangPPlunkettWFludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical eventCancer Chemother Pharmacol1995a361811887781136
   PubMed Web of Science ®Google Scholar
• HuangPRobertsonLEWrightSHigh molecular weight DNA fragmentation: a critical event in nucleoside analogueinduced apoptosis in leukemia cellsClin Cancer Res1995b1100510139816073
   PubMed Web of Science ®Google Scholar
• HuangPBallalKPlunkettWBiochemical characterization of the protein activity responsible for high molecular weight DNA fragmentation during drug-induced apoptosisCancer Res199757340734149270006
   PubMed Web of Science ®Google Scholar
• RobertsonLEChubbSMeynREInduction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2’-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenineBlood1993811431508093345
   PubMed Web of Science ®Google Scholar
• KeatingMJKantarjianHTalpazMFludarabine: a new agent with major activity against chronic lymphocytic leukemiaBlood19897419252473795
   PubMed Web of Science ®Google Scholar
• SorensenJMVenaDAFallavollitaATreatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up reportJ Clin Oncol1997154584659053466
   PubMed Web of Science ®Google Scholar
• KeatingMJKantarjianHO’BrienSFludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemiaJ Clin Oncol1991944491702145
   PubMed Web of Science ®Google Scholar
• ClavioMMiglinoMSprianoMFirst-line fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual diseaseEur J Haematol1998611972039753416
   PubMed Web of Science ®Google Scholar
• StelitanoCMorabitoFKroppMGFludarabine treatment in B-cell chronic lymphocytic leukaemia: response, toxicity and survival analysis in 47 casesHaematologica19998431732310190945
   PubMed Web of Science ®Google Scholar
• BoogaertsMAVan HoofACatovskyDActivity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemiaJ Clin Oncol2001194252425811709569
   PubMed Web of Science ®Google Scholar
• RossiJFvan HoofAde BoeckKEfficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemiaJ Clin Oncol2004221260126715051774
   PubMed Web of Science ®Google Scholar
• RaiKRPetersonBLAppelbaumFRFludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukaemiaN Engl J Med20003431750175711114313
   PubMed Web of Science ®Google Scholar
• JohnsonSSmithAGLöfflerHMulticentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLLLancet1996347143214388676625
   PubMed Web of Science ®Google Scholar
• LeporrierMChevretSCazinBRandomized comparison of fludarabine, CAP and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukaemia patientsBlood2001982319232511588025
   PubMed Web of Science ®Google Scholar
• SprianoMChiurazziFCassibbaVMulticentric prospective randomised trial of fludarabine versus chlorambucil and prednisone in previously untreated patients with active B-chronic lymphocytic leukaemia (B-CLL): first interim reportBr J Haematol1998102191
   Web of Science ®Google Scholar
• EichhorstBFBuschRObwandnerTHealth-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study GroupJ Clin Oncol2007251722173117389338
   PubMed Web of Science ®Google Scholar
• O’BrienSKantarjianHBeranMResults of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatmentBlood199382169517008400226
   PubMed Web of Science ®Google Scholar
• DhönerHFischerKBentzMp53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemiasBlood199585158015897888675
   PubMed Web of Science ®Google Scholar
• ValgañónMGiraldoPAgirreXp53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IVBr J Haematol2005129535915801955
   PubMed Web of Science ®Google Scholar
• BellosilloBVillamorNColomerDIn vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemiaBlood1999942836284310515887
   PubMed Web of Science ®Google Scholar
• KoehlULiLNowakBFludarabine and cyclophosphamide: synergistic cytotoxicity associated with inhibition of interstrand cross-link removalProc Am Assoc Cancer Res1997382
   Google Scholar
• GandhiVNowakBKeatingMJModulation of arabinosylcytosine metabolism by arabinosyl–2-fluoroadenine in lymphocytes from patients with chronic ymphocytic leukemia: implications for combination therapyBlood198974207020752478221
   PubMed Web of Science ®Google Scholar
• SeymourJFHuangPPlunkettWInfluence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion scheduleClin Cancer Res199626536589816215
   PubMed Web of Science ®Google Scholar
• YangL-YLiLKeatingMJPlunkett W. Arabinosyl–2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repairMol Pharmacol199547107210797746274
   PubMed Web of Science ®Google Scholar
• ZaffaroniNOrlandiLGornatiDFludarabine as a modulator of cisplatin activity in human tumour primary cultures and established cell linesEur J Cancer199632A176617738983288
   PubMed Web of Science ®Google Scholar
• KnaufWUKreuserEDPottgiesserEIn vitro and in vivo effectiveness of fludarabine in B-cell chronic lymphocytic leukemia (B-CLL)Ann Hematol199265A80
   Google Scholar
• EliasLStock-NovackDHeadDRA phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a Southwest Oncology Group studyLeukemia199373613657680398
   PubMed Web of Science ®Google Scholar
• WeissMSpiessTBermanEConcomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukaemiaLeukemia19948129012938057664
   PubMed Web of Science ®Google Scholar
• MorrisonVARaiKRPetersonBLImpact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011J Clin Oncol2001193611362111504743
   PubMed Web of Science ®Google Scholar
• O’BrienSKantarjianHMCortesJResults of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemiaJ Clin Oncol2001191414142011230486
   PubMed Web of Science ®Google Scholar
• FlinnIWJemiaiYBennettJMFludarabine and cyclophosphamide achieves high complete response rate in patients with previously untreated chronic lymphocytic leukemia: ECOG 1997Blood200098633a
   Web of Science ®Google Scholar
• EichhorstBFBuschRHopfingerGFludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukaemiaBlood200610788589116219797
   PubMed Web of Science ®Google Scholar
• StilgenbauerSEichhorstBFBuschRBiologic and Clinical Markers for Outcome after Fludarabine (F) or F Plus Cyclophosphamide (FC) – Comprehensive Analysis of the CLL4 Trial of the GCLLSGBlood20081122089a18596229
   PubMed Web of Science ®Google Scholar
• FlinnIWNeubergDSGreverMRPhase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997J Clin Oncol20072579379817283364
   PubMed Web of Science ®Google Scholar
• CatovskyDRichardsSMatutesEAssessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trialLancet200737023023917658394
   PubMed Web of Science ®Google Scholar
• CazinBDivineMLeprêtreSHigh efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemiaBr J Haematol2008143545918710390
   PubMed Web of Science ®Google Scholar
• LaurentiLTarnaniMDe PaduaLOral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response durationAnn Hematol20088789189818587576
   PubMed Web of Science ®Google Scholar
• BoschFFerrerALopez-GuillermoAFludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemiaBr J Haematol200211997698412472576
   PubMed Web of Science ®Google Scholar
• BoschFFerrerAVillamorNFludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradicationClin Cancer Res20081415516118172266
   PubMed Web of Science ®Google Scholar
• MauroFRFoaRMeloniGFludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patientsHaematologica20028792693312217804
   PubMed Web of Science ®Google Scholar
• RobertsonLEO’BrienSKantarjianHFludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia, Leukemia19959943945
   Google Scholar
• RummelMJKaferGPfreundschuhMFludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German multicenter phase II studyAnn Oncol19991018318810093687
   PubMed Web of Science ®Google Scholar
• RummelMJStilgenbauerSGammHFludarabine versus fludarabine plus epirubicin in the treatment of chronic lymphocytic leukemia (CLL)– preliminary results of a randomized phase-III multi-center studyBlood2002100384a
   Web of Science ®Google Scholar
• GandhiVRobertsonLEKeatingMJCombination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacologyCancer Chemother Pharmacol19943430368174200
   PubMed Web of Science ®Google Scholar
• GilesFJO’BrienSMSantiniVSequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II studyLeuk Lymphoma199936576510613450
   PubMed Web of Science ®Google Scholar
• O’BrienSMooreJOBoydTERandomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukaemiaJ Clin Oncol2007251114112017296974
   PubMed Web of Science ®Google Scholar
• Chanan-KhanAMillerKCTakeshitaKResults of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL)Blood20051063348335216051743
   PubMed Web of Science ®Google Scholar
• LaurentiLPiccioniPTarnaniMLow-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukaemiaLeuk Res20073125325616815546
   PubMed Web of Science ®Google Scholar
• HuhnDvon SchillingCWilhelmMRituximab therapy for patients with B-chronic lymphocytic leukemiaBlood2001981326133111520778
   PubMed Web of Science ®Google Scholar
• ByrdJCMurphyTHowardRSRituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicityJ Clin Oncol2001192153216411304767
   PubMed Web of Science ®Google Scholar
• O’BrienSKantarjianHThomasDARituximab dose-escalation trial in chronic lymphocytic leukaemiaJ Clin Oncol20011921657011304768
   PubMed Web of Science ®Google Scholar
• ByrdJCPetersonBLMorrisonVARandomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)Blood200310161412393429
   PubMed Web of Science ®Google Scholar
• WierdaWO’BrienSWenSChemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemiaJ Clin Oncol2005234070407815767647
   PubMed Web of Science ®Google Scholar
• KeatingMJO’BrienSAlbitarMEarly results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemiaJ Clin Oncol2005234079408815767648
   PubMed Web of Science ®Google Scholar
• ByrdJCRaiKPetersonBLAppelbaumFRAddition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011Blood2005105495315138165
   PubMed Web of Science ®Google Scholar
• TamCSO’BrienSWierdaWLong-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemiaBlood200811297598018411418
   PubMed Web of Science ®Google Scholar
• LinKITamCSKeatingMJRelevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimensBlood2008122[Epub ahead of print].
   Web of Science ®Google Scholar
• HallekMFingerle-RowsonGFinkAMImmunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)Blood2008112325a
   Web of Science ®Google Scholar
• FoonKABoyiadzisMLandSRChemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemiaJ Clin Oncol20081215[Epub ahead of print].
   PubMedGoogle Scholar
• TsimberidouAMWierdaWGPlunkettWPhase I–II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter’s syndrome or fludarabine-refractory chronic lymphocytic leukemiaJ Clin Oncol20082619620318182662
   PubMed Web of Science ®Google Scholar
• BoschFAbrisquetaPVillamorNRituximab, fludarabine, fyclophosphamide, and mitoxantrone (R-FCM) is a highly active chemoimmunotherapy regimen for chronic lymphocytic leukemiaBlood20081122097a
   Web of Science ®Google Scholar
• KeatingMJFlinnIJainVTherapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international studyBlood2002993554356111986207
   PubMed Web of Science ®Google Scholar
• HillmenPSkotnickiABRobakTAlemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemiaJ Clin Oncol2007255616562317984186
   PubMed Web of Science ®Google Scholar
• MontilloMTedeschiAMiqueleizSAlemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemiaJ Clin Oncol2006242337234216618945
   PubMed Web of Science ®Google Scholar
• WendtnerCMRitgenMSchweighoferCDConsolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)Leukemia2004181093110115071604
   PubMed Web of Science ®Google Scholar
• KennedyBRawstronACarterCCampath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemiaBlood2002992245224711877305
   PubMed Web of Science ®Google Scholar
• ElterTBorchmannPSchulzHFludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trialJ Clin Oncol2005237024703116145065
   PubMed Web of Science ®Google Scholar
• WierdaWFaderlSO’BrienSCombined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) Is Active for Relapsed and Refractory Patients with CLLBlood2004104340a15054046
   PubMed Web of Science ®Google Scholar
• WierdaWO’BrienSFerrajoliACombined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Frontline Regimen for High-Risk Patients with CLLBlood2007110628a
   Web of Science ®Google Scholar
• MontilloMMiqueleizSTedeschiACombined Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC), an Active Regimen for Treated Patients with Chronic Lymphocytic Leukemia (CLL)Blood20071103133a
   Web of Science ®Google Scholar
• ElterTJamesRWendtnerCMTreatment of patients with relapsed/refractory CLL using a combination of fludarabine, cyclophosphamide and alemtuzumab: First safety analysis of the CLL2L trial of the German CLL Study GroupJ Clin Oncol2008267053a
   Web of Science ®Google Scholar
• ByrdJCastroJO’BrienSComparison of results from a phase 1/2 study of lumiliximab (Anti-CD23) in combination with FCR for patients with relapsed CLL with published FCR resultsBlood200610832a
   Web of Science ®Google Scholar
• ChamplinRKhouriIAnderliniPNonmyeloablative preparative regimens for allogeneic hematopoietic transplantationBone marrow transplant200127S13S2211436116
   PubMed Web of Science ®Google Scholar
• GiraltSThallPFKhouriIMelphalan and purine analog-containing preparative regimens: reduced intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantationBlood20019763163711157478
   PubMed Web of Science ®Google Scholar
• NaglerASlavinSVaradiGAllogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphomaBone Marrow Transplant2000251021102810828860
   PubMed Web of Science ®Google Scholar
• AnderliniPGiraltSAnderssonBAllogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin’s diseaseBone Marrow Transplant20002661562011041566
   PubMed Web of Science ®Google Scholar
• GiraltSAlemanAAnagnostopoulosAFludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myelomaBone Marrow Transplant20023036737312235521
   PubMed Web of Science ®Google Scholar
• Perez-SimonJAKottaridisPDMartinoRNonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disordersBlood20021003121312712384408
   PubMed Web of Science ®Google Scholar
• BergmannLFenchelKJahnBImmunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemiaAnn Oncol199343713758353071
   PubMed Web of Science ®Google Scholar
• AnaissieEJKontoyiannisDPO’BrienSInfections in patients with chronic lymphocytic leukemia treated with fludarabineAnn Intern Med1998295595669758577
   PubMed Web of Science ®Google Scholar
• ChesonBDInfections and immunosupressive complications of purine analog therapyJ Clin Oncol199513243124487666104
   PubMed Web of Science ®Google Scholar
• BusuttilDPChastyRCCopplestoneJAInfections complicating treatment of lymphoid malignancies with fludarabineBr J Haematol199693Suppl 169
   Google Scholar
• ChesonBDVenaDABarrettJSecond malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemiasJ Clin Oncol1999172454246010561309
   PubMed Web of Science ®Google Scholar
• TamCSSeymourJFPrinceHMTreatment-related myelodysplasia following fludarabine combination chemotherapyHaematologica2006911546155017082012
   PubMed Web of Science ®Google Scholar
• GribbenJGZahriehDStephansKAutologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemiaBlood20051064389439616131571
   PubMed Web of Science ®Google Scholar
• MilliganDWFernandesSDasguptaRResults of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responsesBlood200510539740415117764
   PubMed Web of Science ®Google Scholar
• MauroFRFoaRCerrettiRAutoimmune hemolytic anemia in chronic lymphocytic leukaemia: clinical, therapeutic and prognostic featuresBlood2000952786279210779422
   PubMed Web of Science ®Google Scholar
• RobakTBlonskiJZGora-TyborJSecond malignancies and Richter’s syndrome in patients with chronic lymphocytic leukemia treated with cladribineEur J Cancer20044038338914746857
   PubMed Web of Science ®Google Scholar
• MichalletMThiébautADregerPPeripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP)Br J Haematol200010859560110759719
   PubMed Web of Science ®Google Scholar
• MorganSJSeymourJFGriggAPredictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabineLeukemia2004181034103814990978
   PubMed Web of Science ®Google Scholar
• MicallefINApostolidisJRohatinerAZFactors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin’s lymphomaHematol J2000136737311920216
   PubMedGoogle Scholar
• MontilloMTedeschiARossiVSuccessful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1HLeukemia200418576214586480
   PubMed Web of Science ®Google Scholar
• HallekMSchmittBWilhelmMFludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study GroupBr J Haematol200111434234811529853
   PubMed Web of Science ®Google Scholar
• TsimberidouAMKeatingMJGilesFJFludarabine and mitoxantrone for patients with chronic lymphocytic leukemiaCancer20041002583259115197800
   PubMed Web of Science ®Google Scholar
• DregerPBrandRHanszJTreatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioningLeukemia20031784184812750695
   PubMed Web of Science ®Google Scholar
• SorrorMLMarisMBSandmaierBMHematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemiaJ Clin Oncol2005233819382915809448
   PubMed Web of Science ®Google Scholar
• BrownJRKimHTLiSPredictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemiaBiol Blood Marrow Transplant2006121056106417084369
   PubMed Web of Science ®Google Scholar
• DelgadoJThomsonKRussellNResults of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation StudyBlood20061071724173016239425
   PubMed Web of Science ®Google Scholar
• ScheteligJThiedeCBornhauserMEvidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study GroupJ Clin Oncol2003212747275312860954
   PubMed Web of Science ®Google Scholar